OLMA (Olema Pharmaceuticals) 10-Year RORE % : 0.00% (As of Mar. 2026)


OLMA Olema Pharmaceuticals inc OLMA
35 GF Score
Price $12.64
! 2 Warning Signs
View Full Analysis

What is Olema Pharmaceuticals 10-Year RORE %?

Olema Pharmaceuticals OLMA +4.72% 35 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus rates OLMA with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 614 Biotechnology companies, Olema Pharmaceuticals ranks worse than 162866.29% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Olema Pharmaceuticals does not have enough data to calculate 10-Year RORE %.


Olema Pharmaceuticals  (NAS:OLMA) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Olema Pharmaceuticals 10-Year RORE % Related Terms


Olema Pharmaceuticals 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Olema Pharmaceuticals's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olema Pharmaceuticals 10-Year RORE % Chart

Olema Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
10-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Olema Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OLMA vs DRTS, ORIC, KURA: 10-Year RORE % Comparison

For the Biotechnology subindustry, Olema Pharmaceuticals's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Olema Pharmaceuticals 10-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Olema Pharmaceuticals's 10-Year RORE % falls into.


OLMA
35GF Score
Olema Pharmaceuticals inc OLMA
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Olema Pharmaceuticals 10-Year RORE % Calculation

Olema Pharmaceuticals's 10-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 0.00 mean?
Olema Pharmaceuticals (OLMA) has a 10-Year RORE % of 0.00 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Olema Pharmaceuticals and its competitors. According to the industry distribution chart, Olema Pharmaceuticals ranks #999999 out of 614 companies in the Biotechnology industry.
Is Olema Pharmaceuticals' 10-Year RORE % too high?
Olema Pharmaceuticals' current 10-Year RORE % is 0.00. Based on the distribution chart, Olema Pharmaceuticals ranks #999999 out of 614 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Olema Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Olema Pharmaceuticals' 10-Year RORE % compare to DRTS and ORIC?
According to the Biotechnology industry distribution chart, Olema Pharmaceuticals ranks #999999 out of 614 companies for 10-Year RORE %. This places Olema Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Biotechnology company?
A good 10-Year RORE % depends on the Biotechnology industry context. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Olema Pharmaceuticals and its competitors. Olema Pharmaceuticals's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olema Pharmaceuticals stock overvalued right now?
Olema Pharmaceuticals (OLMA) has a current 10-Year RORE % of 0.00. The current 10-Year RORE % is 0.00. Olema Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Olema Pharmaceuticals (OLMA), the current 10-Year RORE % is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Olema Pharmaceuticals Business Description

Address 780 Brannan Street, San Francisco, CA, USA, 94103
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
35GF Score

Get the complete analysis for OLMA

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.64
Price